5-[4-(1-pyrrolidinyl)-phenyl]-2-thienylsulfonyl chloride | 1098299-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 5-[4-(1-pyrrolidinyl)-phenyl]-2-thienylsulfonyl chloride
• 英文别名: 5-(4-Pyrrolidin-1-ylphenyl)thiophene-2-sulfonyl chloride
• CAS: 1098299-27-4
• 化学式: C₁₄H₁₄ClNO₂S₂
• 分子量: 327.856
• InChiKey: GAUNWDVFSNDTGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  74
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Certain azacycloalkyl substituted acetic acid derivatives
  申请人：——

  公开号：US20040235896A1

  公开（公告）日：2004-11-25

  Compounds of the formula (I) wherein R represents OH or NHOH; R 1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R 2 represents biarylsulfonyl or aryloxyarylsufonyl; R 3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R 4 and R 5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals. 1

  式(I)化合物，其中R代表OH或NHOH；R1代表氢、可选择性取代的低级烷基、芳基-低级烷基、环烷基-低级烷基或源自羧酸、碳酸、氨基甲酸或磺酸的酰基；R2代表双芳基磺酰基或芳氧基芳基磺酰基；R3代表氢、可选择性取代的低级烷基、芳基-低级烷基、环烷基-低级烷基或源自羧酸、碳酸或氨基甲酸的酰基；R4和R5各自独立地代表氢、低级烷基、低级烷氧羰基、芳基-低级烷基或环烷基-低级烷基；m为0、1、2或3；其药学上可接受的药物前体衍生物；其药学上可接受的盐；包含所述化合物的药物组合物；以及它们用于抑制基质降解金属蛋白酶和预防或治疗哺乳动物中依赖基质金属蛋白酶的状况的用途。
• Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors
  申请人：Fujimoto Aki Roger

  公开号：US20070060569A1

  公开（公告）日：2007-03-15

  Compound of the formula wherein R represents OH or NHOH; R 1 represents hydrogen, optically substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid or from a sulfonic acid; R 2 represents biarylsulfonyl or aryloxyrylsulfonyl; R 3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or from a carbamic acid; R 4 and R 5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.

  该公式的化合物中，R代表OH或NHOH; R1代表氢、光学取代的较低烷基、芳基-较低烷基、环烷基-较低烷基或由羧酸、碳酸、氨基甲酸或磺酸衍生的酰基; R2代表双芳基磺酰基或芳氧基芳基磺酰基; R3代表氢、可选取代的较低烷基、芳基-较低烷基、环烷基-较低烷基或由羧酸、碳酸或氨基甲酸衍生的酰基; R4和R5分别独立地代表氢、较低烷基、较低烷氧羰基、芳基-较低烷基或环烷基-较低烷基; m为零、1、2或3; 其药物可接受的前药衍生物; 其药物可接受的盐; 包括所述化合物的制药组合物; 以及它们用于抑制基质降解金属蛋白酶并预防或治疗哺乳动物基质金属蛋白酶依赖性疾病的用途。
• AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES FOR USE AS MMP INHIBITORS
  申请人：Novartis AG

  公开号：EP1373262B1

  公开（公告）日：2010-05-12
• [EN] CERTAIN AZACYCLOALKYL SUBSTITUTED ACETIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDE ACETIQUE SUBSTITUES AZACYCLOALKYLE
  申请人：NOVARTIS AG

  公开号：WO2002072577A2

  公开（公告）日：2002-09-19

  Compounds of the formula (I) wherein R represents OH or NHOH; R1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyarylsufonyl; R3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R4 and R5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals.